Cannabis Law Report

JULY 19, 2021

There is an urgent need for objective, scientifically sound and robust clinical trials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). Extensive early phase experience with appropriate safety oversight and early phase clinic.

Clinical Trials 98

Clinical Trials Research and Development Hybrid Medicine 98

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. “We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of Clinical Development & Regulatory Affairs.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. Los Angeles, California. www.InvestorBrandNetwork.com.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Veriheal

APRIL 11, 2022

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. This means that the medical and scientific communities can now celebrate broader access to research for the production of pharmaceutical products that are safer than smokable or vaporizable cannabis. Drug Enforcement Agency (DEA). federal law.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 7, 2021

Company plans to initiate Phase II trial with a leading academic institution. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The BioMAP Diversity PLUS Panel provides biologically relevant in vitro models of human disease and is used to analyze drug candidate compounds, from discovery to preclinical safety.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Cannabis Law Report

DECEMBER 20, 2021

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Ganaxolone was generally well-tolerated and no new safety findings emerged in the LGS subgroup. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. About MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

AUGUST 5, 2021

Additionally, the technology backed by the patent will be essential for transforming variable psychedelic raw materials into pharmaceutical-grade standardized extracts. This approval represents important progress in the development of our intellectual property,” Benjamin Lightburn, CEO of Filament, said in a press release. “At

Extraction 105

Extraction Clinical Trials Research and Development Pharmaceutical 105

Cannabis Law Report

JULY 28, 2021

This includes First Time in Human (“FTiH”) clinical trials, which are expected to commence in 2022, for the Group’s lead compound OCT461201, a selective cannabinoid receptor type 2 (“CB2”) agonist with initial indications in the areas of post herpetic neuralgia and visceral pain caused by irritable bowel syndrome.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

MMJ Recs

APRIL 1, 2024

Furthermore, ongoing clinical trials are investigating CBD’s efficacy in treating conditions such as multiple sclerosis, Parkinson’s disease, and substance abuse disorders. By promoting relaxation and reducing anxiety, CBD may help individuals achieve restful sleep without the need for pharmaceutical interventions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

The Cannigma

FEBRUARY 1, 2023

To date, very few human clinical trials have been conducted to assess the effectiveness of THC or CBD in treating cancer. While RSO has been subject to increased popularity in treating certain types of cancers, no clinical trials have tested the safety or efficacy of RSO in humans, meaning that all evidence is anecdotal.

Clinical Trials 145

Clinical Trials Research and Development Therapy Cannabinoids 145

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

JUNE 17, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. It covers the pipeline drug profiles, including clinical and nonclinical stage products. Ganaxolone: Marinus Pharmaceuticals. Epilepsy Emerging Drugs.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Project CBD

NOVEMBER 11, 2023

In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. So just on safety alone, it’s worth using it. I include pharmaceutical drugs in that category. In general, I think that botanical medicine is safer than pharmaceutical medicine.

Medicine 301

Medicine Research and Development Pharmaceutical Cannabis 301

Canna Law Blog

NOVEMBER 15, 2021

With ketamine as the only psychedelic treatment that can (currently) be legally prescribed and administered “off label” by licensed physicians, many entrants into the psychedelic space have started with operating ketamine clinics, with the goal of expanding to other psychedelic treatments when legally permissible.

Clinical Trials 98

Clinical Trials Treatment Microdosing Pharmaceutical 98

Cannabis Law Report

JUNE 21, 2021

Algernon Pharmaceuticals Inc. OTC: EHVVF) adds Dr. Jeffrey Kamlet, an expert on cardiac safety in ibogaine treatment, as Chief Medical Officer. retains CRO Sante Cannabis to conduct clinical trials in psilocybin therapies. (CSE: ENBI). 0.0395 -0.125 (-24.04%). 0.135 -0.025 (-15.62%). Red Light Holland Corp. CSE: TRIP).

Clinical Trials 66

Clinical Trials Research and Development Therapy Pharmaceutical 66

Canna Care Docs

OCTOBER 3, 2023

However, many of these pharmaceutical medications can just induce more unpleasant, debilitating effects on those who are ill. Depending on the type of terminal illness diagnosed by the doctor, there are numerous pharmaceutical and conventional medications provided for patients to treat the symptoms that come with a terminal illness.

Chronic Pain 105

Chronic Pain Clinical Trials Patients Cannabinoids 105

Cannabis Law Report

DECEMBER 8, 2021

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. The results of this study underscore the safety of our spray film technology.”. About Virpax Pharmaceuticals.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Weedistry

FEBRUARY 4, 2019

First, plenty of pharmaceutical drugs, that we broadly accept as legitimate medicine, received approval from the U.S. And the safety and efficacy of those drugs aren’t even buttressed by a mountain of anecdotal evidence — unlike cannabis use, which has thousands of years of documentation. doesn’t mean it doesn’t work.

Clinical Trials 40

Clinical Trials Pharmaceutical Chronic Pain Safety 40

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., The clinical trial results confirmed more than 80% of dogs showed significant or dramatic improvement. Wakshlag, DVM, Ph.D.,

Safety 45

Safety CBD Clinical Trials Oil 45

The Joint Blog

JUNE 2, 2020

The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Pain intensity and safety parameters were recorded on a 10-cm visual analogue scale (VAS) at pre-defined time points.

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

NOVEMBER 22, 2019

“As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development.

DEA 66

DEA Clinical Trials THC Research and Development 66

The Cannigma

MARCH 7, 2022

What can the current clinical trials tell us? A common theme with cannabis is that more research is needed, so thankfully there are clinical trials in the works looking at the therapeutic utility of CBN. Those recruited will apply either CBN cream or placebo to non-wounded areas over a course of 28 days.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

JUNE 21, 2021

Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Taking the doctor-patient use of RYAH devices one step further, organizations conducting clinical trials are finding value in the company’s offerings.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

JUNE 15, 2021

This landmark investment and strategic transaction solidifies Brains’ position as one of the leading pharmaceutical companies in the cannabinoid (CBD) sector. To have the confidence of DSM in this next round solidifies Brains strategic position within the pharmaceutical industry,” said Brains’ CEO & Chairman Rick Brar.

Pharmaceutical 82

Pharmaceutical Clinical Trials Research and Development Events 82

Cannabis Law Report

MARCH 1, 2022

Focus will be on IND/CTA filings and associated interactions, and may include safety reports, protocols, information amendments, responses to requests for information, IND Annual Reports/DSURs, and new investigator amendments. 10 years of experience in the pharmaceutical industry. +5 5 years of hands-on regulatory experience.

Clinical Trials 52

Clinical Trials Environment Pharmaceutical Programs 52

Cannabis Law Report

SEPTEMBER 12, 2022

Our mushrooms are some of the most tested products on the planet as we cross the lines between Pharmaceutical, Agriculture, Botanical, and Food testing quality assays,” said Optimi Chief Science Officer, Justin Kirkland. The harvest includes the following psilocybin-containing mushroom strains: Koh Samui. Penis Envy. Blue Pulaski.

History 52

History Clinical Trials Legalization Research and Development 52